0
     

Report Added
Report already added
Hospital Acquired Pneumonia (HAP) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Hospital Acquired Pneumonia (HAP) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hospital Acquired Pneumonia (HAP) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline landscape.

Hospital Acquired Pneumonia (HAP) is defined as pneumonia acquired during hospital stay. Symptoms include cough, fever, shaking chills, confusion, headache and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hospital Acquired Pneumonia (HAP) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia (HAP) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hospital Acquired Pneumonia (HAP) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 5, 4, 11, 15, 12 and 2 respectively.

Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hospital Acquired Pneumonia (HAP) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hospital Acquired Pneumonia (HAP) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hospital Acquired Pneumonia (HAP) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hospital Acquired Pneumonia (HAP) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hospital Acquired Pneumonia (HAP) - Overview
Hospital Acquired Pneumonia (HAP) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Hospital Acquired Pneumonia (HAP) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hospital Acquired Pneumonia (HAP) - Companies Involved in Therapeutics Development
AiCuris AG
Allecra Therapeutics GmbH
Antabio SAS
Aridis Pharmaceuticals Inc
Biolytx Pharmaceuticals Corp
Bioversys AG
Cellular Biomedicine Group Inc
Centauri Therapeutics Ltd
Clarametyx Biosciences Inc
ContraFect Corp
Cumberland Pharmaceuticals Inc
CytaCoat AB
Destiny Pharma Plc
Dong-A Socio Holdings Co Ltd
Eldec Pharmaceuticals Inc
Entasis Therapeutics Holdings Inc
Evotec SE
GangaGen Biotechnologies Pvt Ltd
Helperby Therapeutics Group Ltd
Hoth Therapeutics Inc
Hypo-Stream Ltd
La Jolla Pharmaceutical Company
Meiji Seika Pharma Co Ltd
Merck & Co Inc
Nabriva Therapeutics Plc
Nosopharm SAS
Omnix Medical Ltd
Peptineo
Pfizer Inc
Pherecydes Pharma SA
Phico Therapeutics Ltd
Pulmobiotics SL
Qilu Pharmaceutical Co Ltd
Revagenix Inc
Shionogi & Co Ltd
Spero Therapeutics Inc
Spexis AG
TGV-Inhalonix Inc
Therapeutic Systems Research Laboratories Inc
VenatoRx Pharmaceuticals Inc
Wockhardt Ltd
Hospital Acquired Pneumonia (HAP) - Drug Profiles
(AAI-101 + cefepime) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(avibactam + aztreonam) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(avibactam sodium + ceftazidime) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(cefepime + taniborbactam hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(cefepime + zidebactam) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(cilastatin sodium + imipenem + relebactam) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(durlobactam sodium + sulbactam) - Drug Profile
Product Description
Mechanism Of Action
History of Events
ABX-01 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AlloJoin - Drug Profile
Product Description
Mechanism Of Action
History of Events
arbekacin - Drug Profile
Product Description
Mechanism Of Action
History of Events
Biologic for Ventilator Associated Pneumonia - Drug Profile
Product Description
Mechanism Of Action
BP-002 - Drug Profile
Product Description
Mechanism Of Action
History of Events
cefiderocol sulfate tosylate - Drug Profile
Product Description
Mechanism Of Action
History of Events
CF-370 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CMTX-101 - Drug Profile
Product Description
Mechanism Of Action
EBX-004 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ELD-607 - Drug Profile
Product Description
Mechanism Of Action
History of Events
eravacycline dihydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
exeporfinium chloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
FL-058 - Drug Profile
Product Description
Mechanism Of Action
History of Events
fosfomycin disodium - Drug Profile
Product Description
Mechanism Of Action
History of Events
HT-006 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HY-010B3 - Drug Profile
Product Description
Mechanism Of Action
HY-011B4 - Drug Profile
Product Description
Mechanism Of Action
HY-012B5 - Drug Profile
Product Description
Mechanism Of Action
HY-015B12 - Drug Profile
Product Description
Mechanism Of Action
lefamulin acetate - Drug Profile
Product Description
Mechanism Of Action
History of Events
levonadifloxacin - Drug Profile
Product Description
Mechanism Of Action
MEMANT-3310 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Mul-1867 - Drug Profile
Product Description
Mechanism Of Action
History of Events
murepavadin - Drug Profile
Product Description
Mechanism Of Action
History of Events
nacubactam - Drug Profile
Product Description
Mechanism Of Action
History of Events
NOSO-2G - Drug Profile
Product Description
Mechanism Of Action
History of Events
OMN-6 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Panaecin - Drug Profile
Product Description
Mechanism Of Action
History of Events
panobacumab - Drug Profile
Product Description
Mechanism Of Action
History of Events
Peptides for Complicated Skin and Skin Structure Infections and Hospital Acquired Pneumonia (HAP) - Drug Profile
Product Description
Mechanism Of Action
History of Events
PP-1231 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Proteins to Inhibit Peptidoglycan (Murein) for Bacterial Infections, Cystic Fibrosis, Hospital Acquired Pneumonia and Diabetic Foot Infection - Drug Profile
Product Description
Mechanism Of Action
History of Events
Qn-2251 - Drug Profile
Product Description
Mechanism Of Action
rifabutin - Drug Profile
Product Description
Mechanism Of Action
History of Events
SASPjectPT-3.9 - Drug Profile
Product Description
Mechanism Of Action
Small Molecule for Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
Small Molecules for Hospital Acquired Pneumonia (HAP) and Ventilator Associated Pneumonia (VAP) - Drug Profile
Product Description
Mechanism Of Action
Small Molecules for Hospital-Acquired Pneumonia, Intra-Abdominal and Urinary Tract Infections - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules for Infectious Diseases - Drug Profile
Product Description
Mechanism Of Action
sodium hypochlorite - Drug Profile
Product Description
Mechanism Of Action
SPR-206 - Drug Profile
Product Description
Mechanism Of Action
History of Events
suvratoxumab - Drug Profile
Product Description
Mechanism Of Action
History of Events
tedizolid phosphate - Drug Profile
Product Description
Mechanism Of Action
History of Events
telavancin hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
tosatoxumab - Drug Profile
Product Description
Mechanism Of Action
History of Events
XF-70 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Hospital Acquired Pneumonia (HAP) - Dormant Projects
Hospital Acquired Pneumonia (HAP) - Discontinued Products
Hospital Acquired Pneumonia (HAP) - Product Development Milestones
Featured News & Press Releases
Aug 17, 2021: Venatorx Pharmaceuticals provides update on Cefepime-Taniborbactam
Jun 07, 2021: The results of a preclinical trial demonstrating the benefits of inhaled Pherecydes Pharma phages in treating ventilation-associated pneumonia have been published in the prestigious British Journal of Pharmacology
Apr 19, 2021: Phico Therapeutics awarded up to $18.2 million USD CARB-X funding to advance SASPject antibacterial therapy through phase 1 clinical trials
Apr 19, 2021: Phico Therapeutics awarded up to $18.2 million USD CARB-X funding to advance SASPject antibacterial therapy through phase 1 clinical trials
Oct 16, 2020: CHMP adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Recarbrio
Oct 16, 2020: CHMP adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Recarbrio
Sep 18, 2020: AstraZeneca receives CHMP positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Zavicefta
Sep 18, 2020: AstraZeneca receives CHMP positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Zavicefta
Jun 25, 2020: CHMP recommended extensions of indication for Zavicefta
Jun 25, 2020: CHMP recommended extensions of indication for Zavicefta
Jun 04, 2020: FDA approves antibiotic to treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
Jun 04, 2020: FDA approves antibiotic to treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
Jun 01, 2020: FDA accepts Shionogi’s Supplemental New Drug Application with Priority Review for FETROJA (cefiderocol) for the Treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia
May 06, 2020: Antabio receives FDA qualified infectious disease product (QIDP) designation for MEM-ANT3310, a novel broad-spectrum combination therapy targeting WHO’s priority pathogens
May 06, 2020: Antabio receives FDA qualified infectious disease product (QIDP) designation for MEM-ANT3310, a novel broad-spectrum combination therapy targeting WHO’s priority pathogens
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Hospital Acquired Pneumonia (HAP), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Products under Development by Companies, 2022 (Contd..4)
Products under Development by Companies, 2022 (Contd..5)
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by AiCuris AG, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Allecra Therapeutics GmbH, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Antabio SAS, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Aridis Pharmaceuticals Inc, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Biolytx Pharmaceuticals Corp, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Bioversys AG, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Cellular Biomedicine Group Inc, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Centauri Therapeutics Ltd, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Clarametyx Biosciences Inc, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by ContraFect Corp, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Cumberland Pharmaceuticals Inc, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by CytaCoat AB, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Destiny Pharma Plc, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Dong-A Socio Holdings Co Ltd, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Eldec Pharmaceuticals Inc, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Entasis Therapeutics Holdings Inc, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Evotec SE, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by GangaGen Biotechnologies Pvt Ltd, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Helperby Therapeutics Group Ltd, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Hoth Therapeutics Inc, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Hypo-Stream Ltd, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by La Jolla Pharmaceutical Company, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Meiji Seika Pharma Co Ltd, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Merck & Co Inc, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Nabriva Therapeutics Plc, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Nosopharm SAS, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Omnix Medical Ltd, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Peptineo, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Pfizer Inc, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Pherecydes Pharma SA, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Phico Therapeutics Ltd, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Pulmobiotics SL, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Qilu Pharmaceutical Co Ltd, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Revagenix Inc, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Shionogi & Co Ltd, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Spero Therapeutics Inc, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Spexis AG, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by TGV-Inhalonix Inc, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Therapeutic Systems Research Laboratories Inc, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by VenatoRx Pharmaceuticals Inc, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Wockhardt Ltd, 2022
Hospital Acquired Pneumonia (HAP) - Dormant Projects, 2022
Hospital Acquired Pneumonia (HAP) - Dormant Projects, 2022 (Contd..1)
Hospital Acquired Pneumonia (HAP) - Dormant Projects, 2022 (Contd..2)
Hospital Acquired Pneumonia (HAP) - Discontinued Products, 2022

List of Figures
Number of Products under Development for Hospital Acquired Pneumonia (HAP), 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

Report Title: Hospital Acquired Pneumonia (HAP) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

Veterinary Pain Management Market by Product (Drug (NSAIDs, Opioids), Route of Administration (Oral, Parenteral), Device (Laser)), Application (Joint Pain, Cancer), Animal (Companion and Livestock), End User (Hospital, Pharmacy) - Global Forecast to 2027

Veterinary Pain Management Market by Product (Drug (NSAIDs, Opioids), Route of Administration (Oral, Parenteral), Device (Laser)), Application (Joint Pain, Cancer), Animal (Companion and Livestock), End User (Hospital, Pharmacy) - Global Forecast to 2027

Patient Monitoring Devices Market by Product (EEG, MEG, TCD, Pulse Oximeter, Spirometer, Fetal Monitor, Temperature Monitor, MCOT, ECG, ICP, ILRs, Multi-parameter Monitoring, Weight Monitoring), End-User (Hospital, ASCs) - Global Forecast to 2027

Patient Monitoring Devices Market by Product (EEG, MEG, TCD, Pulse Oximeter, Spirometer, Fetal Monitor, Temperature Monitor, MCOT, ECG, ICP, ILRs, Multi-parameter Monitoring, Weight Monitoring), End-User (Hospital, ASCs) - Global Forecast to 2027

US Transdermal Patch Market Opportunity & Clinical Trials Insight 2028

US Transdermal Patch Market Opportunity & Clinical Trials Insight 2028

Asia Pacific Single Cell Multiomics Market 2021-2031 by Product Type (Instruments, Consumables, Software), Omics Type (SCG, SCT, SCP, SCM), Application (Clinical Research, Translation Research, Synthetic Biology), Sample Type (Human, Animal, Microbial), Workflow (Single-Cell Isolation and Dispensing, Single-Cell Analysis), End User (Research and Academic Laboratories, Biopharma and Biotech Companies, CROs, Others), and Country: Trend Forecast and Growth Opportunity

Asia Pacific Single Cell Multiomics Market 2021-2031 by Product Type (Instruments, Consumables, Software), Omics Type (SCG, SCT, SCP, SCM), Application (Clinical Research, Translation Research, Synthetic Biology), Sample Type (Human, Animal, Microbial), Workflow (Single-Cell Isolation and Dispensing, Single-Cell Analysis), End User (Research and Academic Laboratories, Biopharma and Biotech Companies, CROs, Others), and Country: Trend Forecast and Growth Opportunity

Europe Single Cell Multiomics Market 2021-2031 by Product Type (Instruments, Consumables, Software), Omics Type (SCG, SCT, SCP, SCM), Application (Clinical Research, Translation Research, Synthetic Biology), Sample Type (Human, Animal, Microbial), Workflow (Single-Cell Isolation and Dispensing, Single-Cell Analysis), End User (Research and Academic Laboratories, Biopharma and Biotech Companies, CROs, Others), and Country: Trend Forecast and Growth Opportunity

Europe Single Cell Multiomics Market 2021-2031 by Product Type (Instruments, Consumables, Software), Omics Type (SCG, SCT, SCP, SCM), Application (Clinical Research, Translation Research, Synthetic Biology), Sample Type (Human, Animal, Microbial), Workflow (Single-Cell Isolation and Dispensing, Single-Cell Analysis), End User (Research and Academic Laboratories, Biopharma and Biotech Companies, CROs, Others), and Country: Trend Forecast and Growth Opportunity

North America Single Cell Multiomics Market 2021-2031 by Product Type (Instruments, Consumables, Software), Omics Type (SCG, SCT, SCP, SCM), Application (Clinical Research, Translation Research, Synthetic Biology), Sample Type (Human, Animal, Microbial), Workflow (Single-Cell Isolation and Dispensing, Single-Cell Analysis), End User (Research and Academic Laboratories, Biopharma and Biotech Companies, CROs, Others), and Country: Trend Forecast and Growth Opportunity

North America Single Cell Multiomics Market 2021-2031 by Product Type (Instruments, Consumables, Software), Omics Type (SCG, SCT, SCP, SCM), Application (Clinical Research, Translation Research, Synthetic Biology), Sample Type (Human, Animal, Microbial), Workflow (Single-Cell Isolation and Dispensing, Single-Cell Analysis), End User (Research and Academic Laboratories, Biopharma and Biotech Companies, CROs, Others), and Country: Trend Forecast and Growth Opportunity